Survey of pharmacists to evaluate the effectiveness of the Viagra Connect national additional Risk Minimisation Measure (aRMM) in the United Kingdom (UK) (NA)

Study type

• Study topic:
  Human medicinal product

  Disease /health condition
• Study type:
  Non-interventional study
• Scope of the study:
  Effectiveness study (incl. comparative)
• Data collection methods:
  Primary data collection

Non-interventional study

• Non-interventional study design:
  Cross-sectional

Study drug and medical condition

• Anatomical Therapeutic Chemical (ATC) code:
  (G04BE03) sildenafil
• Medical condition to be studied:
  Erectile dysfunction

Population studied

• Short description of the study population:
  Pharmacists who have received at least one patient request to supply Viagra Connect within the six months preceding the survey administration. ; Pharmacists must meet all of the following inclusion criteria:; 1. Willing/consent to participate in this self-administered survey (Answered “Yes” to a survey question asking “Do you agree to proceed with this survey”);; 2. A practicing pharmacist in the UK;; 3. Received at least one patient face-to-face request to supply Viagra Connect in the past six months.
• Age groups:
  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Estimated number of subjects:
  200

Study design details

• Main study objective:
  To evaluate the effectiveness of the Viagra Connect national aRMM by assessing: • The pharmacists’ knowledge of the key risk messages contained in the Viagra Connect training materials, • The pharmacists’ participation in the Viagra Connect pharmacist training,• The pharmacists’ utilisation of the optional Viagra Connect Pharmacy Checklist at the point of dispensing.
• Data analysis plan:
  Data collected from the survey will be reported as descriptive statistics. No statistical inferences will be made. Frequency distributions with 95% confidence intervals (CIs) will be calculated for pharmacist’s responses to all questions that address the survey objectives. Survey data will be stratified by participating in the training and by other key pharmacist’s characteristics if sample sizes are large enough (ie, no less than 25 in the minority group).

Documents

Study results

a1481334-report-body